2025
Longitudinal CNS and systemic T-lymphocyte and monocyte activation before and after antiretroviral therapy beginning in primary HIV infection
Chan P, Li X, Li F, Emu B, Price R, Spudich S. Longitudinal CNS and systemic T-lymphocyte and monocyte activation before and after antiretroviral therapy beginning in primary HIV infection. Frontiers In Immunology 2025, 16: 1531828. PMID: 40070827, PMCID: PMC11893981, DOI: 10.3389/fimmu.2025.1531828.Peer-Reviewed Original ResearchConceptsCerebrospinal fluid HIV RNAPrimary HIV infectionT cell activationCD8+ T cell activationAntiretroviral therapyHIV RNACD4+HIV infectionCerebrospinal fluidT cellsMonocyte activationNeuronal injuryCD4+ T cell activationCD8<sup>+</sup> T cellsCD8+ T cellsFrequencies of activated CD4+ART-naive peopleChronic HIV infectionTrafficking of immune cellsAntiretroviral therapy initiationChemokine receptor expressionMultiparameter flow cytometryImmune cell activationSurface marker expressionCentral nervous system
2022
Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study
Trickey A, Zhang L, Gill MJ, Bonnet F, Burkholder G, Castagna A, Cavassini M, Cichon P, Crane H, Domingo P, Grabar S, Guest J, Obel N, Psichogiou M, Rava M, Reiss P, Rentsch CT, Riera M, Schuettfort G, Silverberg MJ, Smith C, Stecher M, Sterling TR, Ingle SM, Sabin CA, Sterne JAC. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. The Lancet HIV 2022, 9: e404-e413. PMID: 35659335, PMCID: PMC9647005, DOI: 10.1016/s2352-3018(22)00046-7.Peer-Reviewed Original ResearchConceptsIntegrase strand inhibitorsCause mortalityCohort studyThird drugAntiretroviral drugsMortality rateAntiretroviral Therapy Cohort CollaborationFirst-line ART regimensUK Collaborative HIV CohortART-naive peopleCollaborative HIV CohortAntiretroviral therapy regimensUK Medical Research CouncilMedical Research CouncilCohort CollaborationEfavirenz regimensVirological benefitVirological failureVirological suppressionART regimensHIV cohortHazard ratioRoutine careTherapy regimensUS National Institutes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply